Lilly focuses on tau with AC Immune Alzheimer’s R&D tie-upEli Lilly has paid $81m to develop drugs targeting aggregation of tau proteins associated with Alzheimer’s with Swiss Share XLilly focuses on tau with AC Immune Alzheimer’s R&D tie-uphttps://pharmaphorum.com/news/lilly-focuses-on-tau-with-ac-immune-alzheimers-rd-tie-up/
CarThera raises €9m to tackle the blood-brain barrierFrench company CarThera has raised €9 million in its Series B funding round to help it develop ultrasound-based Share XCarThera raises €9m to tackle the blood-brain barrierhttps://pharmaphorum.com/news/carthera-raises-e9m-to-tackle-the-blood-brain-barrier/
WuXi AppTec eyes acquisitions after $1bn Hong Kong IPOChinese biotech WuXi AppTec has completed its listing on Hong Kong’s HKEX, raising $967m just months after making Share XWuXi AppTec eyes acquisitions after $1bn Hong Kong IPOhttps://pharmaphorum.com/news/wuxi-apptec-eyes-acquisitions-after-1bn-hong-kong-ipo/
Neurocrine slumps as Tourette’s drug fails clinical trialShares in Neurocrine Biosciences slumped by as much as a fifth after a much-anticipated trial in Tourette’s syndrome missed Share XNeurocrine slumps as Tourette’s drug fails clinical trialhttps://pharmaphorum.com/news/neurocrine-slumps-as-tourettes-drug-fails-clinical-trial/
Axovant axes neuroscience drug, focuses on gene therapiesSwiss biotech Axovant started the year badly, dropping its Alzheimer’s drug intepirdine after it failed in a trial, Share XAxovant axes neuroscience drug, focuses on gene therapieshttps://pharmaphorum.com/news/axovant-axes-neuroscience-drug-focuses-on-gene-therapies/
Eisai, Takeda and GARDP hunt for new antibioticsThe not-for-profit Global Antibiotic Research and Development Partnership has joined forces with Eisai and Takeda to search for Share XEisai, Takeda and GARDP hunt for new antibioticshttps://pharmaphorum.com/news/eisai-takeda-and-gardp-hunt-for-new-antibiotics/
FDA clears Pear/Sandoz app for opioid use disorderA second mobile app developed by Pear Therapeutics to help opioid use disorder patients who have a more Share XFDA clears Pear/Sandoz app for opioid use disorderhttps://pharmaphorum.com/news/fda-clears-pear-sandoz-app-for-opioid-use-disorder/
Boehringer follows Sanofi with job cuts in FranceBoehringer Ingelheim has confirmed it plans to axe more than 10% of its workforce in France, or more Share XBoehringer follows Sanofi with job cuts in Francehttps://pharmaphorum.com/news/boehringer-follows-sanofi-with-job-cuts-in-france/
AZ and CRUK team up to go all-in on CRISPRAstraZeneca and Cancer Research UK are collaborating to launch a centre of excellence in genetic screening, cancer modelling Share XAZ and CRUK team up to go all-in on CRISPRhttps://pharmaphorum.com/news/az-cruk-crispr/
